39861 Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial - 25/09/23
Doi : 10.1016/j.jaad.2023.07.589
Il testo completo di questo articolo è disponibile in PDF.
| Commercial Support: This study was sponsored by Bristol Myers Squibb. |
© 2023
Pubblicato da Elsevier Masson SAS.
Vol 89 - N° 3S
P. AB147 - settembre 2023 Ritorno al numero
Articolo precedente
- 43110 Deucravacitinib, a Selective Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: PASI Body Region and Component Scores in a Phase 3 Trial
- Yayoi Tada, Shinichi Imafuku, Yukari Okubo, Mamitaro Ohtsuki, Yanqiu Shao, Elizabeth Colston, Andrew Napoli, Lauren Hippeli, Subhashis Banerjee, Akimichi Morita
- 43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
- Richard B. Warren, April W. Armstrong, Shinichi Imafuku, Carle Paul, Leon Kircik, Elizabeth Colston, Thomas Scharnitz, Tao Wang, Subhashis Banerjee, Bruce Strober
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?